Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

This review discusses the acyl-CoA synthetase very-long-chain (ACSVL) enzyme family, including its biochemical characteristics, tissue expression, and involvement in lipid metabolism, but presents no new experimental results.

This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.

This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.

In this reported case, a 13-year-old boy with alopecia areata experienced complete lesion resolution and varied hair regrowth across different laser treatment parameters after three months of combined oral prednisone, topical ointment, and CO2 fractional laser therapy.

In this study, the combination of low level light therapy with arginine, arterial extract, or biotin tripeptide-1 was associated with improvements in hair density and follicle structure in androgenic alopecia.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study found that the treatment group experienced a higher average increase in hair counts than the placebo group, but the difference was not statistically significant.

This study suggests that combining the 5α-reductase inhibitor 4-MA with the antiandrogen Flutamide may improve prostate cancer therapy by additively inhibiting prostatic growth and androgen-sensitive functions in rats.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This study explored a new treatment for Alopecia Areata, combining high negative pressure microdermabrasion with intralesional steroid injections, and compared its effects to steroid injections alone, although the abstract does not report specific outcomes.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study detailed the implementation of an autonomous AI device in an NHS skin cancer pathway, showing that it achieved a sensitivity of 97.3% for diagnosing skin cancers and exceeded sensitivity targets compared to specialists with a negative predictive value over 99.7%.

This study found that GPT-4o demonstrated high concordance with in-person and image-based provider assessments in generating SALT scores for alopecia areata, suggesting its potential as an adjunct tool in clinical practice for automating these assessments.

This study found that a single injection of autologous cell micrografts significantly improved hair condition in women with androgenetic alopecia six months post-treatment.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

This study found that vibration assisted analgesia reduced pain during intralesional corticosteroid therapy for hair loss, enabling treatment in a broader range of patients, including those with needle phobia.

This study suggests that topical Cyclosporin A formulations, with or without a penetration enhancer, effectively stimulated hair regrowth in a rat model of alopecia areata.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

This study highlights that azelaic acid, initially recognized for skin hypopigmentation, shows potential in treating various skin conditions due to its complex mechanisms, even though these are not yet fully understood, indicating a need for further research.

This study provides a comprehensive analysis of anabolic-androgenic steroids, reporting that their use enhances muscle mass but is associated with significant health issues including cardiac muscle hypertrophy, liver disease, and changes in gender characteristics, emphasizing the need for patient awareness of these risks.

In this study, deletion of ROBO4 in mice ameliorated hair loss caused by elevated PAF levels, suggesting potential interplay with VLDLR-related pathways.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.